This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Baxter (BAX) Soars to a 52-Week High, Time to Cash Out?
by Zacks Equity Research
Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.
4 Medical Device Stocks with Solid Potential to Buy Now
by Zacks Equity Research
The Medical Device tax suspension spells good times for MedTech bigwigs.
Surmodics (SRDX) Hits Fresh Highs: Is There Still Room to Run?
by Zacks Equity Research
Surmodics, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for SRDX for clues.
Surmodics (SRDX) Gains From Consistent Efforts to Boost R&D
by Zacks Equity Research
Surmodics' (SRDX) consistent focus on research and development activities has been driving growth. The company is expected to make continued progress throughout the remainder of fiscal 2018.
Zacks.com featured highlights include: Marine Products, Illumina, Chemed, Surmodics and MAM
by Zacks Equity Research
Zacks.com featured highlights include: Marine Products, Illumina, Chemed, Surmodics and MAM
Baxter International (BAX) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.
5 Top Efficient Stocks to Keep on Your Radar
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
Surmodics (SRDX) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
Surmodics, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for SRDX for clues.
Surmodics (SRDX) Beats on Q2 Earnings & Revenues, Raises View
by Zacks Equity Research
Surmodics' (SRDX) second-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.
SRDX or HAE: Which is a Better Medical Product Stock?
by Zacks Equity Research
Here we analyze the financials and fundamental factors of Haemonetics (HAE) and Surmodics (SRDX) to decide which is a better investment option.
Here's Why You Should Invest in Surmodics (SRDX) Right Now
by Zacks Equity Research
Surmodics (SRDX) continues to benefit from solid growth in the In Vitro Diagnostics (IVD) segment.
Can The Uptrend Continue for Surmodics (SRDX)?
by Zacks Equity Research
Investors certainly have to be happy with Surmodics, Inc. (SRDX) and its short term performance
Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips
by Zacks Equity Research
Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips
5 Top-Ranked Efficient Stocks to Boost Your Portfolio
by Tirthankar Chakraborty
A company with a favorable efficiency level will provide impressive returns irrespective of market conditions
3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax
by Zacks Equity Research
Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.
Abbott to Strengthen Vascular Care Arm With Surmodics Deal
by Zacks Equity Research
Abbott (ABT) gains traction from its newly acquired rights over the SurVeil drug-coated balloon, which shows greater potential for capturing the market compared with traditional devices.
Surmodics (SRDX) Beats on Earnings in Q1, Guidance Solid
by Zacks Equity Research
Solid performance in the In Vitro Diagnostics segment drives Surmodics (SRDX) in first-quarter fiscal 2018.
Surmodics (SRDX) Poised on Core Business Amid Forex Woes
by Zacks Equity Research
Surmodics' (SRDX) top line benefits from strong sales in Medical Device and IVD businesses. However, foreign currency is a headwind.
New Strong Sell Stocks for January 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
SurModics (SRDX) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
SurModics' (SRDX) stellar fourth-quarter results benefit from higher product sales, royalties, research, development and other revenues.
Surmodics Receives FDA's Approval for PTA Balloon Catheter
by Zacks Equity Research
Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.
Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet
by Zacks Equity Research
Surmodics' (SRDX) promising data on SurVeil DCB will boost its fortunes in the symptomatic peripheral artery disease space.
Surmodics (SRDX) Beats Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Surmodics (SRDX) received IDE approval from the FDA for its TRANSCEND SurVeil DCB pivotal study in the third quarter. An upbeat guidance raises investor confidence.
Why Is Surmodics (SRDX) Down 2.7% Since the Last Earnings Report?
by Zacks Equity Research
Surmodics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SurModics (SRDX) Beats Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Surmodics, Inc. (SRDX) reported earnings of 19 cents per share in the first-quarter of fiscal 2017 surpassing the Zacks Consensus Estimate of 9 cents.